#ESMO22: Amgen spotlights confirmatory win for KRAS G12C player Lumakras in lung cancer — but there’s plenty more data to come

PARIS — Amgen came to Paris with a two-step plan to reveal confirmatory CodeBreak 200 trial data for its KRAS G12C drug Lumakras in non-small cell lung cancer. After tipping its cards ahead of the conference to stake a top-line claim — sans data — on hitting the primary endpoint...

Click to view original post